Unfortunately, this assay has a narrow linear range, and is not sensitive enough for the analysis of full plasma UA concentration-time profiles after intravenous uricase. Herein, we developed an LC-MS method with excellent sensitivity, high specificity, simple preparation procedures and a short analytical time, which was efficient for analyzing plasma samples at different sampling times after the intravenous infusion of uricase. The efficacy of a new uricase product for injection that was prepared by Escherichia coli has for the first time been investigated in humans.
Introduction
Uric acid (UA) is the final product of purine nucleotide metabolism in humans. An increase in the plasma UA level often occurs in situations of metabolic alterations or disease appearance, such as hyperuricemia, gout, 1 renal failure and metabolic syndrome et al. 2, 3 Therefore, the determination of the plasma UA concentration has been used as a significant indicator in clinical assays.
To date, several methods have been developed to determine plasma levels of UA.
Enzymatic approaches 4 and phosphotungstate methods 5 have a lack of sensitivity and are imprecise; electrochemical assays 6 can also be interfered by ascorbic acid and dopamine in biological samples. Although high-performance liquid chromatography with ultraviolet absorbance (HPLC-UV), 7, 8 or gas chromatography-tandem mass spectrometry (GC-MS) 9 as a chromatographic method has been developed to measure UA levels, they all have their limitations. The LC techniques have provided the desired sensitivity, but they all lack of good selectivity and high specificity, mainly due to interference in the matrix. Additional sample clean-up also limits their efficiency and capacity. On the other hand, derivatization is essential in the sample-preparation procedure for analytes with GC-MS.
Recently, rasburicase, a recombinant urate oxidase (uricase), has been approved as an alternative to allopurinol for the management of plasma uric acid levels in clinical trials. 10 During rasburicase administration, the plasma uric acid levels should be monitored regularly. 11 To monitor this therapy, an assay with high sensitivity, selectivity and reproducibility seems to be necessary. Hence, liquid chromatography-tandem mass spectrometry (LC-MS) analytical methods that can offer a powerful tool for the determination of biological substances have been introduced as a means for determining plasma UA concentrations. Dai et al. published an LC-isotope dilution mass spectrometry (ID-MS) method as an alternative reference method for the analysis of serum uric acid.
However, additional sample preparation and a relatively long analytical time are needed in this type of study. Subsequently, Kim et al. developed an LC-MS/MS method, and have used it to measure intracellular and extracellular uric acid.
1,3-15 N uric acid, the internal standard (IS), was purchased from ISOTEC (Great Neck, NY). They were of at least 98% purity. Methanol was of LC-MS grade and formic acid was of LC grade, and purchased from Tedia (Tedia Co. Inc., Fairfield, OH). All other chemicals were of AR grade available from commercial sources. Recombinant urate oxidase for injection was obtained from Weihai Anjie Medical Biotech Co., Ltd. (Shandong, China).
Instrumentation and experimental conditions
A 1200 Agilent series HPLC and a 6410 Agilent Triple Quadrupole mass spectrometer equipped with an electrospray ionization source were used (Agilent Technologies, USA). Data acquisition was performed with an Agilent 6410 Quantitative Analysis software, and data processing was carried out using Agilent MassHunter Workstation Software. Separation was achieved using a TC-C18 column (4.6 × 250 mm, 5 μm, Agilent Technologies, USA) coupled with a Gemini C18 guard column (4 × 3.0 mm, Phenomenex, USA). The mobile phase consisted of 30% water (containing 0.5% formic acid) and 70% methanol, and the flow rate was 1.0 mL/min. The total run time was 3.5 min. The injection volume was 5.0 μL, and the column oven temperature was set at 35 C.
The multiple reaction monitoring (MRM) mode was selected to monitor the precursor-to-product ion transitions of m/z 169.1 → m/z 141.1 for uric acid and m/z 171 → m/z 143 for 1,3- 15 N uric acid (IS) at the positive ionization mode. The optimal instrument parameters of the mass spectrometer were as follows: gas temperature, 300 C; gas flow, 9 L/min; nebulizer pressure, 40 psi; capillary voltage, 4000 V; fragmentor voltage, 100 V (uric acid) and 120 V (IS); collision energy, 13 eV for both uric acid and IS.
Preparation of the stock solutions
Stock solutions of uric acid (1 g/L) and the internal standard of 1, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] N urate (1 g/L) were prepared with boric acid buffer (pH 8.63). All of the stock solutions were kept at 4 C.
Preparation of standard plasma samples for calibration curves and quality control (QC)
After 40 mL of plasma obtained from healthy volunteers was incubated with 200 μL uricase (7.5 mg/L) for 2 h, the processed blank human plasma could eliminate the interference of endogenous UA. Calibration curves of uric acid were prepared at concentration levels of 100, 40, 16, 6.4, 2.56, 1.024, 0.4096 mg/L by spiking 180 μL of processed blank human plasma with 20 μL of an appropriate amount of the standard solution. QC samples were prepared at 1.024, 6.40 80 mg/L. All samples were stored at 4 C.
Sample preparations
After 200 μL of a plasma sample was mixed with 600 μL of methanol containing 2.0 mg/L IS, the mixture was vortexed for 3 min, and then centrifuged at 17500g for 10 min; a 5-μL aliquot of the supernatant was injected into the LC-MS/MS system for analysis.
Method validation
The method of UA in human plasma was validated for the specificity, sensitivity, linearity, accuracy, precision, recovery and stability. A test for the specificity of the method was performed in six different sources of blank human plasma, and the corresponding spiked plasma with UA. Each sample was tested by the same preparation procedure, and the analytical conditions mentioned above were used to ensure no interference at the retention time of the UA and IS.
The linearity of the method was evaluated by assaying three calibration curves in human plasma in the range of 0.4096 -100 mg/L. Calibration graphs were obtained by a weighted (1/x 2 ) least-squares linear fitting through measurements of the peak-area ratios of UA to IS versus UA levels in plasma. The acceptance criterion for each back-calculated standard concentration must be within 15% deviation of the nominal value, with the exception of LLOQ, for which the maximum acceptable deviation was set at 20%. The correlation coefficient (r) should also be greater than 0.99.
The analytical accuracy and the precision were examined using QC samples. Five samples of each concentration were then carried through the sample preparation as described above to analyze the intra-and inter-day (on three consecutive days) accuracy and precision. The peak-area ratios of UA to IS were measured. The accuracy and the precision were calculated based on the percentage value of the observed concentration to the theoretical concentration and the relative standard deviation (RSD), respectively. For acceptable values, the intra-and inter-day accuracy should be within 85 -115%. The precision at each concentration was expected to be within 15%.
The recovery and matrix effects of this method were determined at three levels of QC samples (n = 5). The recovery was calculated by comparing the peak areas obtained from spiked plasma samples with those of the analyte solutions at corresponding concentrations. Matrix effects were evaluated by comparing the mean peak areas of the analyte spiked posttreatment to those of the analyte solutions at corresponding concentrations.
Stability experiments were carried out at three QC levels using triplicate for each under different conditions. QC samples were assessed for the short-term room-temperature condition for 4 h, long-term storage conditions at -20 C for 45 days and postpreparative stability of the processed samples at room temperature for over 16 h. The results obtained from these samples were compared to the theoretical concentration, and UA was considered to be stable under various conditions with a deviation of less than 15%.
Enzymatic action of uricase in vitro
To 180 μL of plasma sample (not processed), 20 μL of saline or uricase (1500 U/L) was added. The same preparation procedure was performed, and the processed samples were placed at room temperature for 12 h before analysis. Plasma UA concentrations were compared by the percentage value of the observed concentrations with the presence or absence of uricase. The percentage value should be within 85 -115%, and the RSD values below 15% indicated no enzyme activity in vitro.
Application for efficacy evaluation
The data were obtained from a clinical phase I study in Chinese subjects, including 40 normal healthy volunteers and two male patients with hyperuricemia, who were receiving chemotherapy (unpublished data). The study was performed in accordance with the Declaration of Helsinki; and its amendments; the experimental protocol was approved by the Ethical Committee of Xiangya third hospital, Central South University. Written informed consents were obtained from all subjects before commencing the study.
All healthy subjects were in good health, as indicated by their medical history, physical examinations and routine laboratory tests. All subjects were not allowed to use any drugs, and were asked to abstain from alcohol, caffeine and grapefruit juice for two weeks before the study. Thirty subjects were sequentially assigned to three groups, groups 1 -3 (10 subjects each including 2 placebo). Groups 1 -3 received a single infusion dose of 0.1, 0.2 and 0.3 mg/kg of uricase in 50 mL of saline that lasted 30 min. Blood samples were collected prior to dosing, 0.167, 0.333, 0.5 h during dosing, and 0.5, 1, 2, 4, 6, 10, 14, 24, 36, 48, 60, 72 h after dosing. In the multiple-dose study, subjects were administered at the dosing of 0.2 mg/kg or placebo once a day for 7 days. On day 7, the sampling times were the same as in the single-dose study. For two patients, the infusion dosing of 0.2 mg/kg/day was administered for 7 days. Blood samples were collected prior to dosing on days 1 -7, day 8 (24 h after starting administration on day 7) and day 9 (48 h after starting administration on day 7). Plasma was separated and stored at 4 C until analysis.
The pharmacodynamic parameters for each subject were calculated by non-compartmental analyses using WinNonLin Version 6.1. The area under the plasma uric acid-time curve from 0 to 24 h (AUC0-24h), and the changes of the area under the plasma uric acid-time curve (ΔAUClast) were calculated using a trapezoid ruler. The minimum plasma concentration (Cmin) and the corresponding time (Tmin) were read directly from the concentration-time data. All statistic analysis was performed by using SPSS 17.0 statistics software, and a p-value less than 0.05 was considered to be significant.
Results and Discussion

Method development
Due to the interference of endogenous uric acid, processed plasma was used as a matrix to prepare calibration curves and QC samples. In this method, the mobile phase of 70% methanol and 30% water containing 0.5% formic acid can produce a desirable peak shape with a short run time of 3.5 min. The extraction of analyte and IS with methanol precipitation could also simplify the sample-preparation procedure without evaporation and reconstitution, and the sensitivity could be sufficient for clinical analysis. In contrast to previous reports, 12, 13 MRM was carried out in the positive-ion detection mode. The analytes yielded major [M+H] + ions at m/z 169.1 and 171 for uric acid and IS, respectively. The most sensitive mass transition was m/z 169.1 → m/z 141.1 for uric acid and m/z 171 → m/z 143 for IS. The MRM conditions were optimized for the sensitivity and specificity required for uric acid. Because the signal in the negative-ion detection mode was weak and unstable in our preliminary experiments, we selected the positive-ion detection mode here. This provided excellent sensitivity, a wide linear range and weak matrix effects. Although other matrix components could be eluted with uric acid together, these substrates might not affect the separation and quantification of uric acid. The matrix components, such as inorganic salts, amino acids and proteins, were hardly retained in the C18 column. Therefore, the elution from 0 to 2 min was not injected into MS. The typical chromatograms showed us better peak shapes of uric acid, and the matrix effects also demonstrated that few matrix components interfered with uric acid in the plasma.
Chromatography
The specificity of this method was evaluated by extracting samples of six different batches of blank human plasma. Figure 1 shows typical chromatograms of blank plasma, spiked plasma with uric acid and IS, and the plasma from a volunteer after administration. The retention time of uric acid or IS was about 3.2 min. No significant interfering peaks were observed in human plasma.
Linearity, sensitivity, accuracy and precision
Linear calibration curves were obtained in the range of 0.4096 -100 mg/L by plotting the peak-area ratios of uric acid to IS against the concentrations of the analyte. A good correlation was found between the observed peak area ratios (y) and the theoretical concentration (x). A weighted (1/x 2 ) least-squares regression analysis gave typical regression lines: y = 0.2604x + 0.0048 (r 2 = 0.9925). When a signal-to-noise (S/N) ratio of 10.0 or greater was used as a criterion for a significant response, the lower limit of quantitation (LLOQ) was set at 0.4096 mg/L. The intra-and inter-day accuracy and precision were determined by analyzing QC samples at low, medium, and high concentrations. Data are presented in Table 1 . These results indicated that the LC-MS/MS method was accurate and precise.
Recovery and matrix effects
The extraction recovery of this method was determined at three different concentrations of 1.024, 6.4, 80 mg/L (described above). The extraction recoveries of this assay were 63.7 ± 6.8, 62.7 ± 5.7 and 67.0 ± 0.6% for the low, middle and high concentrations, respectively. The RSD value of matrix effects at each concentration was less than 15%.
Stability and enzyme activity in vitro
Stability tests indicated that uric acid in human plasma was stable under the evaluated conditions. The data showed that the stability of QC samples at room temperature for 4 h, -20 C for 45 days and post-preparative stability at room temperature for 16 h were acceptable (Table 2) . In vitro studies demonstrated that the plasma UA concentrations were the same with the presence or absence of uricase at room temperature for 12 h (Table 3) .
Application
Mean plasma concentration-time profiles are presented in Fig. 2 . The efficacy parameters are listed in Table 4 . The values of the changes of concentration from the baseline (ΔCmax) and ΔAUClast were significantly higher in the 0.3 mg/kg group than those in the 0.1 and 0.2 mg/kg groups, while no significant differences were seen between the cohorts of 0.1 and 0.2 mg/kg. There were also statistical differences in AUC0-24h and Cmin at three single-dose groups. In the multiple-dose group (Table 4) , ΔCmax, ΔAUClast, AUC0-24h and Cmin were significantly different from those obtained in a single-dose group, indicating a greater reduction of the plasma uric acid level. For both patients, the trough concentration of uric acid in plasma was 5.893 ± 1.421 mg/L. Mean plasma concentration-time profiles in two patients are presented in Fig. 3 . As a pharmacodynamic biomarker, the plasma uric acid levels decreased obviously at 12 h after single dosing, with a slow elevation at 36 h (Fig. 2) . Figure 3 shows a significant decrease in plasma uric acid within 24 h after the first dosing in two patients. This low level remained stable until 48 h after the last dosing with a little increase.
The percent maximum decline normalized to the baseline at 0.1, 0.2 and 0.3 mg/kg groups were 84.8, 99.7 and 97.8%, respectively (Fig. 2) . Of importance, in the cohorts of 0.2 and 0.3 mg/kg, the AUC value within 24 h the post infusion remained lower level (100 -150 mg·h/L) ( Table 4 ), indicating that either 0.2 or 0.3 mg/kg was equally effective at reducing the uric acid concentrations in plasma.
According to the pharmacokinetics of uricase, 14 the maximum observed concentration of uricase was reached at approximately 1 h after three single dosing. Considering with both the pharmacokinetic and pharmacodynamic properties of uricase, the uric acid level in plasma clearly showed a decrease with increasing uricase concentrations; however, a time-delay existed between the uric acid minimum concentration and the uricase peak concentration, suggesting that the pharmacological effect takes time to develop.
Conclusions
The present study provides a sensitive and reliable LC-MS/MS method for the determination of uric acid in human plasma. This method has been successfully applied to an efficacy study of a new uricase product produced by Escherichia coli; the main efficacy parameters were first obtained in Chinese healthy subjects. Our findings provide support for a clinical phase II study to determine the efficacy of this uricase product at dose regimens of 0.1 and 0.2 mg/kg once a day.
